Ozmosi | Cendakimab Drug Profile

Product Description

RPC4046, A Novel Anti-interleukin-13 Antibody, Blocks IL-13 Binding to IL-13 alpha1 and alpha2 Receptors (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28455782/)

Mechanisms of Action: IL13 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Cendakimab

Countries in Clinic: Argentina, Australia, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom, United States, Unknown Location

Active Clinical Trial Count: 9

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Eosinophilia|Eosinophilic Esophagitis|Esophageal Diseases|Gastroenteritis|Intestinal Diseases

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success	Latest Trial Update Date	Data Updated
NCT04991935	CC-93538-EE-002	P3	Completed	Intestinal Diseases\|Eosinophilic Esophagitis\|Esophageal Diseases\|Eosinophilia\|Gastroenteritis	2025-08-14	8%	2026-04-07	Primary Endpoints\|Start Date\|Study Completion Date
jRCT2021210067	jRCT2021210067	P3	Recruiting	Gastroenteritis	2026-12-31
2023-506278-10-00	CC-93538-EE-002	P3	Active, not recruiting	Eosinophilic Esophagitis	2026-08-01		2025-05-02	Treatments
2020-004336-16	2020-004336-16	P3	Completed	Eosinophilic Esophagitis	2024-08-29		2025-06-26	Treatments
NCT05214768	CC-93538-EG-001	P3	Completed	Intestinal Diseases\|Gastroenteritis	2024-07-02		2025-10-23	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT05175352	CC-93538-DDI-001	P1	Completed	Eosinophilic Esophagitis	2024-10-11		2024-12-21	Primary Endpoints\|Study Completion Date\|Treatments\|Trial Status
NCT04753697	CC-93538-EE-001	P3	Completed	Eosinophilic Esophagitis	2024-01-11		2024-10-09	Primary Endpoints\|Study Completion Date
jRCT2031210574	jRCT2031210574	P3	Recruiting	Eosinophilic Esophagitis	2027-01-31
jRCT2051200140	jRCT2051200140	P3	Active, not recruiting	Eosinophilic Esophagitis	2025-02-28

Recent News Events

Date	Type	Title
07/26/2024	News Article	Bristol Myers Squibb Reports Second Quarter Financial Results for 2024
09/14/2023	News Article	Bristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
08/15/2023	News Article	An Old Dog with a New Trick… Ellodi's APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
04/03/2023	News Article	Sanofi/Regeneron's Dupixent Performance in Eosinophilic Esophagitis is Paving the Way for Future Therapies in an Underserved and Growing Market, According to Spherix Global Insights

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Cendakimab

Alternative Names: cendakimab, rpc-4046, rpc4046, rpc 4046, cc-93538, cc 93538, cc93538, abt-308, abt308, abt 308, bms-986355, bms986355 Clinical Status: Inactive Latest Update: 2026-04-06 Latest Update Note: Clinical Trial Update